Aptevo Therapeutics Inc.
APVO· Nasdaq
APVOAptevo Therapeutics Inc.
Filed Mar 25, 2020 · 10-K · 85 days after period end · 0001564590-20-012791
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016 |
|---|---|---|---|---|
| Revenue | $9.03M | $6.35M | $2.82M | $8.77M |
| Net Income | -$8.17M | -$14.13M | -$9.76M | -$14.95M |
| EPS Diluted | — | — |
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
| — |
| -$0.74 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2019 · filed Mar 25, 2020 · 85 d after period end
